Centaurus Financial’s Alaunos Therapeutics TCRT Stock Holding History

Centaurus Financial’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-69	Closed	-$31K	–	1877
2018 Q2	$31K	Buy	+69	New	+$43.8K	﹤0.01%	1114

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Centaurus Financial's TCRT Position: Q3 2018 in Review

Centaurus Financial sold out of Alaunos Therapeutics (TCRT) in Q3 2018, closing a stake of 69 shares — an estimated $31K sold.

Centaurus Financial first reported a position in TCRT in Q2 2018 and held it in 1 quarter. The position peaked at $31K in Q2 2018. 131 funds tracked by Wall St. Rank hold TCRT as of Q3 2018.

Centaurus Financial reported no remaining Alaunos Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 69 Alaunos Therapeutics shares in Q3 2018, an estimated $31K.
Centaurus Financial first reported a position in Alaunos Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Alaunos Therapeutics position peaked at $31K in Q2 2018.
131 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.